Somaxon Pharmaceuticals, Inc.

Somaxon Pharmaceuticals, Inc.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Our lead product candidate is Silenor® (doxepin) for the treatment of insomnia. Silenor is a sleep-specific, low-dose (3mg and 6mg), oral tablet formulation of doxepin that is patent-protected for use in insomnia. In contrast to higher-dose doxepin, Silenor is a potent antagonist that appears to selectively block histamine at the H1 receptor without a clinically relevant impact on other neurotransmitter systems. Doxepin at higher doses has been associated with a range of pharmacologic side effects that include anticholenerigic effects (dry mouth, constipation, etc.) and weight gain. In clinical trials, patients taking Silenor generally did not exhibit the side effects associated with higher doses of doxepin.

Contact Details

Office Address

Somaxon Pharmaceuticals, Inc.
3830 Valley Centre Drive, Suite 705-461
San Diego, CA, USA 92130-3323
Phone: (858) 480-0400
Fax: (858) 509-1761

Executives

Co-Founder and Exec. Chairman

Mr. David F. Hale

Chief Exec. Officer

Mr. Richard W. Pascoe

Business Reviews for Somaxon Pharmaceuticals, Inc.

Related Companies